Adaptimmune Therapeutics plc (ADAP)
收市後：
| 前收市價 | 0.8984 |
| 開市 | 0.9201 |
| 買盤 | 0.9504 x 100 |
| 賣出價 | 0.9790 x 300 |
| 今日波幅 | 0.9200 - 1.0800 |
| 52 週波幅 | 0.4200 - 2.0500 |
| 成交量 | |
| 平均成交量 | 2,001,450 |
| 市值 | 249.607M |
| Beta 值 (5 年，每月) | 2.38 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.5400 |
| 業績公佈日 | 2024年3月04日 - 2024年3月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 3.50 |
ZacksAdaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Insider MonkeyAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript March 6, 2024 Adaptimmune Therapeutics plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello and welcome to Adaptimmune’s Fourth Quarter and Year-End Conference Call and Business Update. I will now […]
Insider Monkey15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024. If you want to skip our overview of the European economy and the stock climate, then you can skip ahead to 5 Top Performing European Stocks So Far in 2024. Over the course of the past […]
